Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Flavio, Fantini"'
Autor:
Elisabetta Valcamonica, Barbara Teruzzi, Gabriele De Marco, Alessandra Salmaso, Alfredomaria Lurati, Maurizio Gattinara, Valeria Gerloni, Irene Pontikaki, Flavio Fantini
Publikováno v:
Reumatismo, Vol 58, Iss 1, Pp 31-38 (2011)
Aim of the study: To report adverse events registered in our population affected by JIA and treated with anti-TNFa blockers. Methods: Ninety-five patients were enrolled to be treated with Etanercept, median age 14 years (range 4-34); median duration
Externí odkaz:
https://doaj.org/article/67075b1fe344434c8c196ff820ae76f4
Autor:
Flavio Fantini
Publikováno v:
Reumatismo, Vol 56, Iss 4, Pp 286-292 (2011)
The author commemorates, in the 20th year since his death, Camillo Benso Ballabio, unforgettable figure of rheumatologist, renowned clinician, man of great culture. The most important stages of his life are described, by adding to the biographical sk
Autor:
Valeria Gerloni, A Salmaso, Irene Pontikaki, Flavio Fantini, Alfredomaria Luriati, E. Valcamonica, Maurizio Gattinara, B Teruzzi, Gabriele De Marco
Publikováno v:
Reumatismo, Vol 58, Iss 1, Pp 31-38 (2011)
Aim of the study: To report adverse events registered in our population affected by JIA and treated with anti-TNFa blockers. Methods: Ninety-five patients were enrolled to be treated with Etanercept, median age 14 years (range 4-34); median duration
Autor:
G. De Marco, A Luriati, E. Valcamonica, Irene Pontikaki, Maurizio Gattinara, B Teruzzi, Valeria Gerloni, Flavio Fantini, A Salmaso
Publikováno v:
Reumatismo, Vol 59, Iss 1, Pp 50-56 (2011)
Objectives: To evaluate, in long-term open label prospective study, infliximab as therapeutic choice for Juvenile Idiopathic Arthritis (JIA) non responsive to conventional therapy. Methods: We enrolled to treat with infliximab 78 JIA patients (66 fem
Autor:
Flavio Fantini, A Lurati, Maurizio Gattinara, B Teruzzi, Valeria Gerloni, Rolando Cimaz, A Salmaso
Publikováno v:
Reumatismo, Vol 60, Iss 3, Pp 224-229 (2011)
Background: Puberty is an essential step in bone mass accrual. Growth failure and impairment of sexual maturation are frequent manifestations of chronic illnesses in the paediatric population, and chronic rheumatologic disorders such as juvenile idio
Autor:
A. Soldi, Roberta Gualtierotti, Silvana Zeni, Patrizia Boracchi, Flavio Fantini, C. Lubatti, L. Zahalkova, Francesca Ingegnoli
Publikováno v:
Reumatismo, Vol 60, Iss 4, Pp 249-253 (2011)
Europe PubMed Central
Europe PubMed Central
Nailfold capillaroscopy (NVC) is a simple and non-invasive method used for the assessment of patients with Raynaud's phenomenon (RP) and in the differential diagnosis of various connective tissue diseases. The scleroderma pattern abnormalities (giant
Publikováno v:
ResearcherID
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that affects about 1% of the adult population. RA sufferers not only have a high chronic disease burden, but may also experience increased cardiovascular disease (CVD) and mortality
Feasibility of Different Capillaroscopic Measures for Identifying Nailfold Microvascular Alterations
Autor:
Francesca Ingegnoli, Flavio Fantini, C. Lubatti, Silvana Zeni, Patrizia Boracchi, L. Meani, L. Zahalkova, Roberta Gualtierotti
Publikováno v:
Seminars in Arthritis and Rheumatism. 38:289-295
Objective To ascertain the most reliable and relevant capillaroscopic measurements of nailfold videocapillaroscopy (NVC) by analyzing their inter- and intraobserver agreement and predictive value. Methods We studied 217 subjects (110 with Raynaud's p
Autor:
A. Soldi, Pier Luigi Meroni, Valentina Galbiati, Samantha Griffini, Ennio Giulio Favalli, Massimo Cugno, Francesca Ingegnoli, Flavio Fantini
Publikováno v:
Journal of Autoimmunity. 31:175-179
Objective Increased cardiovascular (CV) risk is a rheumatoid arthritis (RA) hallmark and it has been mainly related to chronic systemic inflammation. Since inflammation is linked to coagulation perturbation, both may play a role in increasing CV risk
Publikováno v:
Annals of the Rheumatic Diseases. 67:1145-1152
Objective: To report adverse events (AEs) seen in a large cohort of patients with juvenile idiopathic arthritis (JIA) treated with tumour necrosis factor (TNF)α blockers (infliximab and etanercept). Methods: All patients with JIA treated with inflix